Rheumatoid arthritis disease-modifying antirheumatic drug intervention and utilization study: Safety and etanercept utilization analyses from the RADIUS 1 and RADIUS 2 registries
The Journal of Rheumatology, 10/20/2010
Gibofsky A et al.
– The RADIUS registries provide a better understanding of the safety of etanercept in patients with RA in the US practice setting.
Adults ? 18 years of age who fulfilled 1987 American Rheumatism Association criteria for RAwere eligible for enrollment in 2 prospective, 5-year, multicenter, observational registries
RADIUS 1 (Rheumatoid Arthritis DMARD Intervention and Utilization Study) enrolled patients with RA who required change in treatment [either an addition or a switch of a biologic or nonbiologic disease-modifying antirheumatic drug (DMARD)]
In RADIUS 2, patients with RA required to start etanercept therapy at entry
Patients seen at frequency determined by their rheumatologist
SAE, SIE, and EMI occurred at rates comparable to those seen in clinical trials
No unexpected safety signals were observed
Rates for SAE, SIE, and EMI in etanercept-treated patients comparable to rates observed in patients receiving methotrexate monotherapy and did not increase with greater exposure to etanercept therapy
MDLinx connects healthcare professionals and patients to tomorrow's important medical news, while providing the pharmaceutical and healthcare industries with highly targeted interactive marketing, education, content, and medical research solutions.